Compare Moderna, Inc. (MRNA) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Thomson Reuters Corp — how do they compare? Moderna, Inc. trades at $62.94 (market cap $24.18B), while Thomson Reuters Corp trades at $101.4 (market cap $45.38B). The key difference: Thomson Reuters Corp is the larger of the two by market cap, and Thomson Reuters Corp pays a 2.5% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | TRI | |
|---|---|---|
Market Cap | $24.18B | $45.38B |
Sector | Health | Industrials |
52-Week High | $81.80 | $178.77 |
52-Week Low | $22.36 | $76.55 |
Enterprise Value | $20.33B | $48.00B |
Dividend Yield | — | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Thomson Reuters (TRI) trades at $104.36, up 2.48% today, with a bullish technical signal and strong support at $102. The company reported Q2 2026 earnings of $0.99 per share, beating estimates, and raised full-year revenue guidance. Fundamentals show robust profitability with a 21.22% net income margin and 8% organic revenue growth, though cash flow trends indicate recent net outflows.
Outlook remains positive driven by AI product adoption and recurring revenue growth, but risks include execution on tech transitions and competitive pressures. Analysts project a 29.8% upside to the $124 high target, with a majority recommending Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
